Serum sulfonylurea receptor-1 as a biomarker of clinical severity and prognosis in patients with traumatic brain injury

Clin Chim Acta. 2022 Mar 1:528:65-73. doi: 10.1016/j.cca.2022.01.018. Epub 2022 Jan 29.

Abstract

Background: Sulfonylurea receptor-1 (Sur1) plays an important role in acute brain injury. We determine whether serum Sur1 concentrations are associated with traumatic severity and clinical outcome after traumatic brain injury (TBI).

Methods: Serum Sur1 concentrations were measured in 100 healthy controls and 138 patients with moderate to severe TBI. Glasgow coma scale (GCS) and Rotterdam computed tomography (CT) classification were recorded to assess traumatic severity. Glasgow outcome scale (GOS) score of 1-3 at posttraumatic 3 months was defined as an unfavorable outcome.

Results: Serum Sur1 concentrations were markedly higher in patients than in controls. Serum Sur1 concentrations of patients were highly correlated with GCS score, Rotterdam CT classification and GOS score. Patients with unfavorable outcome displayed markedly higher serum Sur1 concentrations than those presenting with favorable outcome. Under receiver operating characteristic curve, serum Sur1 concentrations significantly distinguished patients at risk of unfavorable outcome. Serum Sur1 emerged as an independent predictor for unfavorable outcome.

Conclusions: Rising serum Sur1 concentrations are highly correlated with traumatic severity and are independently associated with poor prognosis after TBI, indicating that serum Sur1 may have the potential to be a useful prognostic biomarker of TBI.

Keywords: Biomarkers; Outcome; Prognosis; Severity; Sulfonylurea receptor-1; Traumatic brain injury.

MeSH terms

  • Biomarkers
  • Brain Injuries, Traumatic* / diagnosis
  • Glasgow Coma Scale
  • Humans
  • Prognosis
  • Sulfonylurea Receptors

Substances

  • Biomarkers
  • Sulfonylurea Receptors